RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
GlycoMimetics Stock

GlycoMimetics Revenue 2024

GlycoMimetics Revenue

0 USD

Ticker

GLYC

ISIN

US38000Q1022

WKN

A1W8HZ

In 2024, GlycoMimetics's sales reached 0 USD, a 0% difference from the 10,000 USD sales recorded in the previous year.

The GlycoMimetics Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e77.16-
2028e32.57-
2027e6.52-
2026e1.29-
2025e3.64-
2024e--
20230.01-
20220.08-
20211.16-
202010.16-
2019--
2018--
2017--
20160.02-
201520.07-
201415.03-
20133.99-
201215.26-
20113.81-

GlycoMimetics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into GlycoMimetics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by GlycoMimetics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects GlycoMimetics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of GlycoMimetics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into GlycoMimetics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing GlycoMimetics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on GlycoMimetics’s growth potential.

GlycoMimetics Revenue, EBIT and net profit per share

DateGlycoMimetics RevenueGlycoMimetics EBITGlycoMimetics Net Income
2029e77.16 M undefined0 undefined36.17 M undefined
2028e32.57 M undefined-58.15 M undefined-9.21 M undefined
2027e6.52 M undefined-72.29 M undefined-44.72 M undefined
2026e1.29 M undefined-44.74 M undefined-33.54 M undefined
2025e3.64 M undefined-39.4 M undefined-28.61 M undefined
2024e0 undefined-40.85 M undefined-39.96 M undefined
202310,000 undefined-39.28 M undefined-36.9 M undefined
202280,000 undefined-47.4 M undefined-46.69 M undefined
20211.16 M undefined-63.45 M undefined-63.43 M undefined
202010.16 M undefined-51.51 M undefined-51.03 M undefined
20190 undefined-61.39 M undefined-57.89 M undefined
20180 undefined-51.5 M undefined-48.27 M undefined
20170 undefined-33.93 M undefined-33.28 M undefined
201620,000 undefined-31.91 M undefined-31.81 M undefined
201520.07 M undefined-12.78 M undefined-12.77 M undefined
201415.03 M undefined-11.14 M undefined-11.12 M undefined
20133.99 M undefined-10.61 M undefined-10.61 M undefined
201215.26 M undefined3.64 M undefined3.66 M undefined
20113.81 M undefined-6.08 M undefined-6.11 M undefined

GlycoMimetics stock margins

The GlycoMimetics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of GlycoMimetics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for GlycoMimetics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the GlycoMimetics's sales revenue. A higher gross margin percentage indicates that the GlycoMimetics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the GlycoMimetics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the GlycoMimetics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the GlycoMimetics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the GlycoMimetics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the GlycoMimetics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

GlycoMimetics Margin History

GlycoMimetics Gross marginGlycoMimetics Profit marginGlycoMimetics EBIT marginGlycoMimetics Profit margin
2029e0 %0 %46.88 %
2028e0 %-178.54 %-28.27 %
2027e0 %-1,109.04 %-686.15 %
2026e0 %-3,462.87 %-2,596.17 %
2025e0 %-1,083.79 %-787.06 %
2024e0 %0 %0 %
20230 %-392,752.93 %-368,994.21 %
20220 %-59,250.01 %-58,362.5 %
20210 %-5,469.83 %-5,468.1 %
20200 %-506.99 %-502.26 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %-159,550 %-159,050 %
20150 %-63.68 %-63.63 %
20140 %-74.12 %-73.99 %
20130 %-265.91 %-265.91 %
20120 %23.85 %23.98 %
20110 %-159.58 %-160.37 %

GlycoMimetics Aktienanalyse

What does GlycoMimetics do?

GlycoMimetics Inc is a biopharmaceutical company specializing in the discovery and development of new drugs for the treatment of cancer and inflammatory diseases. The company was founded in 2003 and is headquartered in Rockville, Maryland. GlycoMimetics' business model is based on the application of glycomimetics, a class of molecules that mimic glycoproteins found in cells. These molecules act in various ways, offering unique therapeutic possibilities in the treatment of cancer and inflammatory diseases. The company conducts research and development in various areas, including the discovery of new drugs, preclinical and clinical drug development, and the evaluation of drug candidates for their transition into clinical trials. One of GlycoMimetics' most important developments is a drug called Rivipansel. This medication is used for the treatment of acute pain and crises in patients with sickle cell anemia. A Phase III clinical trial for Rivipansel was successfully completed in 2019. Another significant aspect of GlycoMimetics' business model is its collaboration with other companies specializing in similar technologies. For example, the company has partnered with Apollomics to advance the development of GMI-1271, a drug candidate for the treatment of Acute Myeloid Leukemia (AML). GlycoMimetics has various research and development areas that are crucial for the development and testing of drug candidates in clinical trials. The company has expertise in chemistry and biological sciences and employs researchers and scientists with diverse backgrounds. One of GlycoMimetics' divisions is medicinal chemistry, which focuses on the synthesis of natural compounds and chemical compounds to identify and develop new drug candidates. The company also has expertise in protein diagnostics, which are used to validate target molecules and assess the effectiveness of drug candidates. Another important division of GlycoMimetics is the field of immunology. Here, the company explores the role of glycoproteins in immune reactions and develops drugs for the treatment of autoimmune diseases. Overall, GlycoMimetics has strong research and development capabilities, enabling the company to develop new drug candidates, conduct clinical trials, and achieve successful growth. With its innovative developments and products, GlycoMimetics contributes to the improvement of the health of many patients and is an important player in the biopharmaceutical industry. GlycoMimetics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding GlycoMimetics's Sales Figures

The sales figures of GlycoMimetics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing GlycoMimetics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize GlycoMimetics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in GlycoMimetics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about GlycoMimetics stock

How much revenue did GlycoMimetics generate this year?

GlycoMimetics has achieved a revenue of 0 USD this year.

How much was the turnover of the company GlycoMimetics compared to the previous year?

The revenue of GlycoMimetics has increased by 0% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of GlycoMimetics?

The revenue of GlycoMimetics is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of GlycoMimetics measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of GlycoMimetics so important for investors?

The revenue of GlycoMimetics is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does GlycoMimetics pay?

Over the past 12 months, GlycoMimetics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, GlycoMimetics is expected to pay a dividend of 0 USD.

What is the dividend yield of GlycoMimetics?

The current dividend yield of GlycoMimetics is .

When does GlycoMimetics pay dividends?

GlycoMimetics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of GlycoMimetics?

GlycoMimetics paid dividends every year for the past 0 years.

What is the dividend of GlycoMimetics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is GlycoMimetics located?

GlycoMimetics is assigned to the 'Health' sector.

Wann musste ich die Aktien von GlycoMimetics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of GlycoMimetics from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did GlycoMimetics pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of GlycoMimetics in the year 2023?

In the year 2023, GlycoMimetics distributed 0 USD as dividends.

In which currency does GlycoMimetics pay out the dividend?

The dividends of GlycoMimetics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The GlycoMimetics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von GlycoMimetics

Our stock analysis for GlycoMimetics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GlycoMimetics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.